NEWS
Bosch and Randox join forces for POCT
Randox Laboratories has announced a new partnership with technology firm Bosch, with the goal of making fast and highly precise diagnostics accessible at the point of care. The two companies will invest around €150 million in joint research, development, and sales activities for new tests for the Vivalytic analysis platform provided by Bosch Healthcare.
One goal is the development of a sepsis IVD grade test that will be the first to feature innovative BioMEMS technology. This innovation enables fully automatic testing of up to 250 genetic characteristics (such as pathogens) in one cartridge, in less than 15 minutes. With its Vivalytic analysis platform, Bosch aims to achieve a leading position in the point-of-care molecular diagnostics market. Bosch Healthcare Solutions is joining forces with Randox to accelerate the development and market launch of new tests and to make distribution channels more efficient. The partnership is set to run for more than ten years.
“Globally, healthcare is moving
toward decentralised and personalised diagnostics, that enable rapid interventions and individual treatment plans. With Randox, we want to further expand the test portfolio of our Vivalytic analysis device. Our fully automated molecular-diagnostic PCR tests provide clarity directly at the site of sample collection, shorten waiting times, and take the strain off the healthcare system,” said Marc Meier, Managing Director of Bosch Healthcare Solutions GmbH.
NW Anglia modernises pathology services
North West Anglia NHS Foundation Trust has replaced two legacy laboratory information systems with a single instance of Clinisys WinPath. The trust, which serves a catchment of 800,000 patients in North Cambridgeshire and South Lincolnshire, found itself with two LIMS when it was formed out of the merger of Peterborough and Stamford Hospitals and Hinchingbrooke Health Care in 2017.
The new LIMS, plus an extension of
the ICE order communications and results reporting system to Hinchingbrooke, will bring benefits for patients, staff and GPs by reducing reliance upon paper and delivering faster results to GPs and patients, regardless of where blood samples are taken or tested. In addition, the new system harmonises working practices and makes it easier for clinicians to view the results of tests taken across the Trust’s three hospital sites. The LIMS and ICE deployments also align with the Trust’s digital strategy to integrate a reduced number of IT systems with a new electronic patient record, and will enable further digital improvement projects and the maturing of the pathology network with neighbouring trusts. Pathology services manager Matthew Smith said: “We had two, old systems from when our trusts merged. Our vision is a single LIMS and a single order
communications system, with a harmonised workflow and a single viewer for clinicians, and we have taken an important step towards delivering that. Moving to a new, modern system enables us to improve efficiency and will support the delivery of further projects that will bring patient safety and sustainability benefits.”
The pathology service at Hinchingbrooke was using an older Clinisys product, but the laboratory at Peterborough and Stamford hospitals was using a legacy system installed around 30 years ago. The deployment of Clinisys WinPath enables them to benefit from the advances in pathology IT that have been made since then. The trust’s pathology service is working towards using Clinisys’ data and analysis tools to automatically collect and submit NHS England’s Cancer Outcomes and Services Dataset and to gain more insight into the performance of the laboratories.
New WGS partnership for Quest
Quest Diagnostics and whole genome sequencing (WGS) firm Broad Clinical Labs have announced a research collaboration designed to demonstrate the clinical value of WGS as a first-line genetic test for postnatal diagnosis of developmental delay disorders.
The parties expect to demonstrate that WGS can provide insights – from a single blood test – that are at least as clinically accurate as the multiple conventional tests providers typically use to diagnose a patient.
“WGS has the power to enable a new diagnostic paradigm, where a physician can access genetic insights faster on the patient’s diagnostic journey, without multiple doctor visits and laboratory tests,” said Mark Gardner, Senior Vice President, Molecular Genomics and Oncology at Quest Diagnostics. “Broad is
10
the leader in genomic science and Quest is the leader in laboratory testing at scale, so together we have the right combination of skills to explore the potential of WGS to replace the conventional model.” Nearly 2% of children manifest intellectual disability. Yet, it can take weeks, months, or even years to identify the underlying cause of intellectual disability or developmental delay, causing a ‘diagnostic odyssey’ for patients and their families. Through the collaboration, Quest will
provide de-identified data, including phenotypic (a person’s observable traits), and blood, saliva, and buccal swab specimens it has tested for developmental delays using CMA and other tests. Broad will then perform WGS on the de-identified specimens to determine concordance between the methods.
MAY 2024
WWW.PATHOLOGYINPRACTICE.COM
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60
